Epigenetic Compound Screening Uncovers Small Molecules for Reactivation of Latent HIV-1.

ABSTRACT: During infection with the human immunodeficiency virus type 1 (HIV-1), latent reservoirs are established that circumvent full eradication of the virus by antiretroviral therapy (ART) and are the source for viral rebound after cessation of therapy. As these reservoirs are phenotypically indistinguishable from infected cells, current strategies aim to reactivate these reservoirs, followed by pharmaceutical and immunological destruction of the cells. Here, we employed a simple and convenient cell-based reporter system, which enables sample handling under biosafety level (BSL)-1 conditions, to screen for compounds that were able to reactivate latent HIV-1. The assay showed a high dynamic signal range and reproducibility with an average Z-factor of 0.77, classifying the system as robust. The as

SUBMITTER: Zutz A 

PROVIDER: S-EPMC7927817 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature